Bay Area cancer-detection developer Freenome agreed to go public via a $330 million SPAC merger, securing roughly $240 million in committed PIPE financing from healthcare investors such as Perceptive Advisors and RA Capital. The transaction positions Freenome to fund commercialization of its blood-based multi-cancer screening tests, including SimpleScreen for colorectal cancer, which is under FDA review. Freenome’s CEO said the company is entering public markets at an “inflection point” following pivotal PREEMPT CRC data and a JAMA publication. The deal includes a planned Nasdaq listing and aims to finance manufacturing, regulatory activities, and a potential commercial rollout in 2026 if regulatory clearance is obtained. Market observers note the SPAC path reflects investor appetite for diagnostics companies with near-term commercial prospects, but Freenome will still face reimbursement, competition and evidentiary scrutiny as it scales.